Amniotic Membrane Stem Cell Skin Equivalent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and cultivating epithelial stem/progenitor cells from umbilical cord tissue are inefficient and invasive, lacking reliable sources for skin substitutes, particularly for skin resurfacing and wound healing, which are ethically acceptable and do not pose a significant biomedical burden on patients.
Innovation Solution
The use of stem/progenitor cells isolated from the amniotic membrane of the umbilical cord, which can be differentiated into mesenchymal and epithelial cells, integrated into a scaffold with a biodegradable material, such as polycaprolactone, to create a skin equivalent that can proliferate and differentiate into fibroblasts and keratinocytes, facilitating skin regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for isolating and cultivating epithelial stem/progenitor cells are used, then skin substitutes can be produced, but the process is inefficient and invasive
Solution Approach 1:
The patent extracts and utilizes amniotic membrane tissue from the umbilical cord, which is discarded after birth, as a source of stem/progenitor cells. This extraction approach provides a non-invasive method to obtain cells for skin substitute production, eliminating the need for invasive procedures on patients while maintaining high productivity.
Solution Approach 2:
The patent performs preliminary isolation and cultivation of stem/progenitor cells from amniotic membrane tissue before the actual skin substitute production. By establishing cell banks in advance from ethically sourced amniotic membrane, the system enables rapid and efficient production of skin substitutes without requiring invasive procedures at the time of treatment.
2Reliability
If stem/progenitor cells are isolated from umbilical cord tissue, then skin equivalents can be generated for wound healing, but reliable and ethical cell sources are lacking
Solution Approach 1:
The patent converts the discarded amniotic membrane tissue, which would normally be disposed of after birth, into a valuable source of stem/progenitor cells. This approach transforms waste material into a reliable and ethically acceptable cell source for skin regeneration, eliminating ethical concerns associated with embryonic stem cells and reducing biomedical burden on patients.
Solution Approach 2:
The patent utilizes the natural properties of amniotic membrane tissue to self-support cell proliferation and differentiation. The amniotic membrane provides a native extracellular matrix environment that facilitates the growth and differentiation of stem/progenitor cells into functional skin components, reducing the need for complex external interventions and enhancing reliability.
3Speed
If amniotic membrane stem/progenitor cells are used, then skin equivalents can be produced rapidly, but efficient isolation and cultivation methods are needed
Solution Approach 1:
The patent segments the complex process of skin substitute production into distinct phases: (1) isolation of stem/progenitor cells from amniotic membrane tissue, (2) cultivation and differentiation of cells in controlled conditions, and (3) assembly of skin equivalents on scaffolds. This segmentation enables standardized protocols for each step, achieving rapid production while managing system complexity through modular approaches.
Solution Approach 2:
The patent utilizes parameter changes in culture conditions (such as growth factors, medium composition, and physical cues) to direct the differentiation of stem/progenitor cells into specific skin cell types. By systematically modifying cultural parameters, the system achieves rapid and efficient generation of functional skin equivalents with controlled cell differentiation.
Data Source
AI summary
The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells.